In conclusion, we think that an antibody cocktail targeting ZTA or GM-CSF, IL-8, and GRO-α may block the angiogenesis in NPC, thus reducing metastasis and recurrence and improving the quality of life in patients with advanced NPC or patients after radiotherapy, but further clinical research is warranted. This evidence concerns the gene CXCL1 and nasopharyngeal carcinoma.